← All trials
NCT03567473
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2018
- Primary completion
- Oct 31, 2022
- Completion date
- Oct 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 1616
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OttawaLead sponsor
- University of TorontoCollaborator
- University of OttawaReponsible party - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Alberta Children's Hospital Research InstituteCollaborator
- Childrens Hospital of Eastern OntarioOverall official - principal investigator
- Children's Hospital Research Institute of ManitobaCollaborator
- University of Western OntarioCollaborator
- Research ManitobaCollaborator
- St. Justine's HospitalCollaborator
- University of AlbertaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.